What is AG1321001(drug) used for?

AG1321001(drug) is indicated for Unknown.

Who makes AG1321001(drug)?

AG1321001(drug) is developed by Ahn-Gook Pharmaceuticals Co.,Ltd.

What are the side effects of AG1321001(drug)?

Common side effects include Unknown.

Last reviewed 2026-04-23 · How we verify

AG1321001(drug)

Ahn-Gook Pharmaceuticals Co.,Ltd · Phase 3 active Small molecule

AG1321001 is a small molecule drug that targets the molecular target.

AG1321001 is a small molecule drug that targets the molecular target. Used for Unknown.

At a glance

Generic name	AG1321001(drug)
Sponsor	Ahn-Gook Pharmaceuticals Co.,Ltd
Drug class	Unknown
Target	Unknown
Modality	Small molecule
Therapeutic area	Unknown
Phase	Phase 3

Mechanism of action

AG1321001 works by binding to the molecular target, which results in the desired therapeutic effect.

Approved indications

Unknown

Common side effects

Unknown

Key clinical trials

Therapeutic Confirmatory Clinical Trial to Evaluate the Safety and Efficacy of AG1321001 in Chronic Cougher (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

AG1321001(drug) CI brief — competitive landscape report
AG1321001(drug) updates RSS · CI watch RSS
Ahn-Gook Pharmaceuticals Co.,Ltd portfolio CI